Michelle Dawson posts

Post published on Twitter/X on 14 Jul 2013 00:48

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov External link integrated into the post
Open original post

Information about the link integrated into the post

Clinical trial

Neuren Pharmaceuticals Limited (2014). A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome. ClinicalTrials.gov. Neuren Pharmaceuticals Limited.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Neuren Pharmaceuticals Limited (2014). A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome. ClinicalTrials.gov. Neuren Pharmaceuticals Limited.

Publication date
2014
Identifier
NCT01894958
Authors
Neuren Pharmaceuticals Limited
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Neuren Pharmaceuticals Limited
Metadata source
clinicaltrials.gov

Abstract

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.

Open source